CNTA Stock Analysis: Buy, Sell, or Hold?
CNTA - Centessa Pharmaceuticals plc American Depositary Shares
$40.50
0.32 (0.80%)
â˛
5d:
+1.86%
30d:
+1.73%
90d:
+56.13%
WAIT
LOW Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When CNTA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CNTA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CNTA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CNTA is currently trading at $40.50, which is considered fair based on recent price action.
Technical Outlook: Technically, CNTA is in a strong uptrend. The price is currently testing key support at $39.58. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CNTA is in a strong uptrend. The price is currently testing key support at $39.58. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
48/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
64.2%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- NEUTRAL: Near Wall St target ($44.17)
- WARNING: Composite score 48/100 in the bottom quintile â this cohort historically lags the market
Support & Resistance Levels
Support Level
$39.58
Resistance Level
$40.56
Current Trend
Strong Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-22.64
Wall Street Target
$44.17
(+9.1%)
Share & Embed Analysis
Last updated: August 22, 2026 4:58 PM ET
Data refreshes hourly during market hours. Next update: 5:58 PM
Data refreshes hourly during market hours. Next update: 5:58 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CNTA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Karen M Anderson
SELL
41076 shares
2026-03-26
Karen M Anderson
SELL
10043 shares
2026-03-17
Karen M Anderson
SELL
64768 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$372 | 42 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$563 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 51 HOLD |
|
APLS
Apellis Pharmaceuticals âĻ |
BUY
22 analysts |
$41 | 50 HOLD |
